Page 2 - Evaluate Pharma News Today

Trends in biotechnology in 2022 and 2023 indicate that innovative platforms continue to spur VC investment. We look at current trends and what’s ahead.

Sangamo Therapeutics Inc.’s cost cuts didn’t hurt just the roughly 162 U.S. workers who lost their jobs this month. It’s also a blow to Jerry Walter, who’s lost five family

Sangamo Therapeutics Inc.’s cost cuts didn’t hurt just the roughly 162 U.S. workers who lost their jobs this month. It’s also a blow to Jerry Walter, who’s lost five family

Sangamo Therapeutics Inc.s cost cuts didnt hurt just the roughly 162 U.S. workers who lost their jobs this month. Its also a blow to Jerry Walter, whos lost five relatives and suffered kidney, lung, hearing and heart damage from a rare disease.

In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Click to skip past our discussion of the biotech space and straight to the 5 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds. Alkermes plc (NASDAQ:ALKS), Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) and ImmunoGen, Inc. […]

In this article we present the list of 12 Best Small-Cap Biotech Stocks with Massive Potential According to Hedge Funds.

Neither is doing well this year.

Wood has outperformed the market so far this year.

This list is by no means exhaustive.

SK Pharmteco, a global contract development and manufacturing organization under Korean conglomerate SK Group, said Wednesday that it has acquired the Center for Breakthrough Medicines, a US cell and gene therapy firm. The Korean firm exercised its right to acquire a controlling stake in CBM to obtain the management right of the Philadelphia-based cell and gene therapy CDMO, offering pre-clinical to commercial phase ...